You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Polatuzumab

Showing 26 - 50 of 56
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Polatuzumab Vedotin in Relapsed and Refractory Diffuse Large B

Completed
  • Relapsed Non Hodgkin Lymphoma
  • Refractory Lymphoma
    • Taipei, Taiwan
      National Taiwan University Hospital
    Aug 8, 2021

    Non-Hodgkin Lymphoma Trial in Worldwide (Mosunetuzumab, Polatuzumab vedotin, Tocilizumab)

    Recruiting
    • Non-Hodgkin Lymphoma
    • Buenos Aires, Argentina
    • +18 more
    Aug 10, 2022

    B-cell Non-Hodgkin Lymphoma Trial in Worldwide (Mosunetuzumab (IV), Mosunetuzumab (SC), Polatuzumab vedotin)

    Recruiting
    • B-cell Non-Hodgkin Lymphoma
    • Mosunetuzumab (IV)
    • +4 more
    • Birmingham, Alabama
    • +28 more
    Jan 6, 2023

    Non-Hodgkins Lymphoma Trial in Worldwide (Glofitamab, Atezolizumab, Obinutuzumab)

    Recruiting
    • Non-Hodgkins Lymphoma
    • Charlotte, North Carolina
    • +21 more
    Jan 18, 2023

    Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory DLBCL Trial in Spain, United Kingdom, United States

    Completed
    • Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    • Marietta, Georgia
    • +27 more
    Feb 4, 2022

    Lymphoma, Large B-Cell, Diffuse Trial in Worldwide (Venetoclax, Polatuzumab Vedotin, Rituximab)

    Recruiting
    • Lymphoma, Large B-Cell, Diffuse
    • New York, New York
    • +19 more
    Aug 17, 2022

    B-Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Worldwide (Glofitamab, Obinutuzumab (G), Rituximab (R))

    Active, not recruiting
    • B-Cell Lymphoma
    • Non-Hodgkin Lymphoma
    • Birmingham, Alabama
    • +23 more
    Dec 2, 2022

    DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma
    • +6 more
    • Axicabtagene Ciloleucel
    • +10 more
    • (no location specified)
    Jan 13, 2023

    DLBCL Unclassifiable, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial in Duarte,

    Recruiting
    • Diffuse Large B-Cell Lymphoma Unclassifiable
    • +6 more
    • Duarte, California
    • +1 more
    Oct 1, 2021

    Lymphoma Trial in Worldwide (Bendamustine, Obinutuzumab, Polatuzumab vedotin (Liquid))

    Completed
    Has Results
    • Lymphoma
    • Birmingham, Alabama
    • +61 more
    Oct 18, 2022

    Lymphoma, Mantle-Cell Trial in Czechia (Polatuzumab vedotin, Bendamustine Hydrochloride, Rituximab)

    Not yet recruiting
    • Lymphoma, Mantle-Cell
    • Polatuzumab vedotin
    • +2 more
    • Brno, Czechia
    • +6 more
    May 28, 2021

    Study to Evaluate Effectiveness and Safety of Polatuzumab

    Unknown status
    • Diffuse Large B-Cell Lymphoma (DLBCL)
    • Polatuzumab Vedotin-Piiq
    • Nanjing, Jiangsu, China
      Jiangsu Cancer Hospital
    Nov 10, 2020

    Relapsed Diffuse Large B-cell Lymphoma, Refractory DLBCL Trial in Worldwide (Polatuzumab Vedotin, Mabthera, Ifosfamide)

    Recruiting
    • Relapsed Diffuse Large B-cell Lymphoma
    • Refractory Diffuse Large B-Cell Lymphoma
    • Polatuzumab Vedotin
    • +4 more
    • Graz, Austria
    • +62 more
    Aug 2, 2022

    Diffuse Large B-cell Lymphoma Trial in Worldwide (Mosunetuzumab Intravenous (IV), Mosunetuzumab Subcutaneous (SC), Polatuzumab

    Recruiting
    • Diffuse Large B-cell Lymphoma
    • Mosunetuzumab Intravenous (IV)
    • +3 more
    • Birmingham, Alabama
    • +52 more
    Aug 19, 2022

    Lymphoma, B-Cell Trial in Worldwide (CC-220, Polatuzumab vedotin, Rituximab)

    Withdrawn
    • Lymphoma, B-Cell
    • Boston, Massachusetts
    • +26 more
    Sep 28, 2021

    DLBCL Trial in Worldwide (Polatuzumab Vedotin, Rituximab, Gemcitabine)

    Recruiting
    • Diffuse Large B-Cell Lymphoma
    • Polatuzumab Vedotin
    • +3 more
    • Hollywood, Florida
    • +89 more
    Jan 31, 2023

    Lymphoma Trial in Germany, Poland, United States (Atezolizumab [TECENTRIQ], Obinutuzumab, Polatuzumab Vedotin)

    Completed
    Has Results
    • Lymphoma
    • Atezolizumab [TECENTRIQ]
    • +3 more
    • Los Angeles, California
    • +18 more
    Nov 30, 2020

    Relapsed or Refractory DLBCL Trial in United States (Selinexor, Rituximab, Bendamustine)

    Suspended
    • Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    • Tucson, Arizona
    • +17 more
    Jan 24, 2023

    Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent Trial in Italy (R-DHAP, Pola-R-DHAP)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma Refractory
    • Diffuse Large B-cell Lymphoma Recurrent
    • Alessandria, Italy
    • +39 more
    Jul 28, 2023

    Diffuse Large B-cell Lymphoma Trial in Worldwide (MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin)

    Recruiting
    • Diffuse Large B-cell Lymphoma
    • MB-CART2019.1
    • R-GemOx or BR plus polatuzumab vedotin
    • Graz, Austria
    • +55 more
    Jan 5, 2023

    DLBCL Trial in Worldwide (Polatuzumab Vedotin, Rituximab, Cyclophosphamide)

    Active, not recruiting
    • Diffuse Large B-Cell Lymphoma
    • Polatuzumab Vedotin
    • +7 more
    • Birmingham, Alabama
    • +242 more
    Nov 23, 2022

    DLBCL, Diffuse Large B Cell Lymphoma Trial in Worldwide (R-pola-mini-CHP, R-mini-CHOP)

    Recruiting
    • DLBCL
    • Diffuse Large B Cell Lymphoma
    • Aalborg, Denmark
    • +44 more
    Jul 8, 2021

    B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma Trial in Worldwide

    Recruiting
    • B-Cell Non-Hodgkin Lymphoma
    • +2 more
    • Loncastuximab Tesirine
    • +4 more
    • Pembroke Pines, Florida
    • +19 more
    Jul 22, 2022

    Lymphoma, Non Hodgkin Trial in France, United States (Cyclophosphamide, Doxorubicin, Obinutuzumab)

    Completed
    Has Results
    • Lymphoma, Non Hodgkin
    • Birmingham, Alabama
    • +10 more
    Feb 18, 2020

    Diffuse Large B Cell Lymphoma (DLBCL) Trial in Toronto (glofitamab)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma (DLBCL)
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Sep 18, 2023